Atpase inhibitors for treatment of neurological and non-neurological disorders

WO2026102542A1PCT designated stage Publication Date: 2026-05-21HAPLO THERAPEUTICS INC

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner: HAPLO THERAPEUTICS INC
Filing Date: 2025-11-14
Publication Date: 2026-05-21

Application Information

Patent Timeline

14 Nov 2025

Application

21 May 2026

Publication

WO2026102542A1

IPC: A61K31/7048; A61K31/566; A61K31/585; A61P3/00; A61P25/00; C07J1/00; C07J17/00; C07J41/00; C12Q1/6809; G01N33/48

CPC: A61K31/566; A61K31/585; A61K31/7048; A61P3/00; A61P25/00; C12Q1/6809; G01N33/48; C07J17/005

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

Smart Images

Figure CA2025051532_21052026_PF_FP_ABST

Patent Text Reader

Abstract

The present disclosure relates to methods and compositions for ATPase inhibitors that regulate expression of EHMT1 / 2 and downstream genes SNRPN, and SNURF, increase histone acetylation and / or restoration of chromatin accessibility at target loci, and / or increase expression of KANSL1 and / or CREBBP. Methods useful for treating a disease associated with EHMT1 / EHMT2 or modulated by EHMT1 / EHMT2 inhibition and downstream gene expression (e.g. Prader-Willi Syndrome), or decreased histone acetylation and / or chromatin accessibility at target loci, and / or decreased expression of KANSL1 and / or CREBBP are disclosed.

Need to check novelty before this filing date? Find Prior Art